Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q2 EPS by 55c

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($1.02), $0.55 worse than the analyst estimate of ($0.47).

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Live Ventures (LIVE) Reports Q3 Loss of $0.34
• Innovative Solutions & Support (ISSC) Tops Q3 EPS by 10c